Umang Vohra on Cipla Q4 & Full Year FY23 Results: Strong operating quarter - highest ever revenue with EBITDA crossing INR 5,000 Cr for the first time. Strong momentum across all markets especially One-India business recording double-digit growth and US business posting highest ever quarterly revenue at $ 204 Mn driven by differentiated portfolio. Gearing for the future with innovation driven initiatives in biosimilar and mRNA and putting digital at the centre of all that we do for our patients.

Cipla Q4 & FY20 Results: Strong growth momentum recorded across India, South Africa, US and key emerging markets, despite the challenges in Q4 owing to the COVID-19 crisis. As we embrace a ‘new post-pandemic world’, Umang Vohra shares how Cipla will continue to uphold its pioneering legacy by reimagining healthcare and reinventing the ecosystem; all keeping the patient care at the core. | Cipla